Lessons from animal studies for the treatment of invasive human infections due to uncommon fungi

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 7, 2011, Pages 1447-1466

  Guarro, Josep ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

Author keywords

Animal models; Antifungal drugs; Aspergillosis; Candidiasis; Fungal infections; Fusariosis; Mycosis; Opportunistic fungi; Scedosporiosis; Zygomycosis

Indexed keywords

ALBACONAZOLE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; TERBINAFINE; VORICONAZOLE;

ABSIDIA; ANIMAL EXPERIMENT; ANTIMICROBIAL THERAPY; APOPHYSOMYCES ELEGANS; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FLAVUS; ASPERGILLUS NIDULANS; ASPERGILLUS TERREUS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA RUGOSA; CANDIDA TROPICALIS; CANDIDIASIS; CLADOPHIALOPHORA BANTIANA; CLADOSPORIOSIS; CLAVISPORA LUSITANIAE; CUNNINGHAMELLA BERTHOLLETIAE; DIPODASCUS CAPITATUS; DIPODASCUS CAPITATUS INFECTION; EXOPHIALA DERMATITIDIS; EXOPHIALA OLIGOSPERMA; EXOPHIALA XENOBIOTICA; FONSECAEA MONOPHORA; FONSECAEA MONOPHORA INFECTION; FUNGUS; FUSARIOSIS; FUSARIUM MONILIFORME; FUSARIUM OXYSPORUM; FUSARIUM SOLANI; HUMAN; MUCOR CIRCINELLOIDES; MUCOR RAMOSISSIMUS; MUCORMYCOSIS; MYCOSIS; NEOSCYTALIDIUM DIMIDIATUM; NEOSCYTALIDIUM DIMIDIATUM INFECTION; NONHUMAN; PAECILOMYCES LILACINUS; PAECILOMYCOSIS; PHAEOHYPHOMYCOSIS; PICHIA GUILLIERMONDII; PSEUDALLESCHERIASIS; RHINOCLADIELLA MACKIENZIEI; RHINOCLADIELLA MACKIENZIEI INFECTION; RHIZOPUS MICROSPORUS; RHIZOPUS ORYZAE; SCEDOSPORIUM APIOSPERMUM; SCEDOSPORIUM AURANTIACUM; SCEDOSPORIUM BOYDII; SCEDOSPORIUM PROLIFICANS; TRICHOSPORON ASAHII; TRICHOSPORONOSIS;

ANIMALS; ANTIFUNGAL AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; MYCOSES; OPPORTUNISTIC INFECTIONS; TREATMENT OUTCOME;

EID: 79958813535     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr143     Document Type: Article

References (225)

1. Polak A. Experimental models in antifungal chemotherapy. Mycoses 1998; 41: 1-30.
2. Stevens DA. Animal models in the evaluation of antifungal drugs. J Mycol Medicale 1996; 6: 7-10.
3. Graybill JR. The role of murine models in the development of antifungal therapy for systemic mycoses. Drug Resist Update 2000; 3: 363-83.
4. Clemons KV, Stevens DA. The contribution of animal models of aspergillosis to understanding pathogenesis, therapy and virulence. Med Mycol 2005; 43 Suppl 1: 101-10.
5. Clemons KV, Stevens DA. Animal models testing monotherapy versus combination antifungal therapy: lessons learned and future directions. Curr Opin Infect Dis 2006; 19: 360-4.
6. Clemons KV, Stevens DA. Animal models of Aspergillus infection in preclinical trials, diagnostics and pharmacodynamics: what can we learn from them? Med Mycol 2006; 44 Suppl 1: 119-26.
7. Capilla J, Clemons KV, Stevens DA. Animal models: an important tool in mycology. Med Mycol 2007; 45: 657-84.
8. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-63.
9. de Hoog GS, Guarro J, Gené J et al. Atlas of Clinical Fungi. Utrecht: Centraalbureau voor Schimmelcultures, 2000.
10. Sugar AM, Liu XP. Effect of grapefruit juice on serum voriconazole concentrations in the mouse. Med Mycol 2000; 38: 209-12.
11. Jabra-Rizk MA, Johnson JK, Forrest G et al. Prevalence of Candida dubliniensis fungemia at a large teaching hospital. Clin Infect Dis 2005; 41: 1064-7.
12. Hajjeh RA, Sofair AN, Harrison LH et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004; 42: 1519-27.
13. Chen SCA, Marriott D, Playford EG et al. Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management. Clin Microbiol Infect 2009; 15: 662-9.
14. Mariné M, Pastor FJ, Sahand IH et al. Lack of correlation between abnormal in vitro growth and reduced efficacy of the echinocandins against Candida dubliniensis murine infections. Antimicrob Agents Chemother 2009; 53: 5297-9.
15. Ju JY, Polhamus C, Marr KA et al. Efficacies of fluconazole, caspofungin, and amphotericin B in Candida glabrata p47phox2/2 knockout mice. Antimicrob Agents Chemother 2002; 46: 1240-5.
16. Atkinson BA, Bouthet C, Bocanegra R et al. Comparison of fluconazole, amphotericin B and flucytosine in treatment of a murine model of disseminated infection with Candida glabrata in immunocompromised mice. J Antimicrob Chemother 1995; 35: 631-40.
17. Olson JA, Adler-Moore JP, Smith PJ et al. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. Antimicrob Agents Chemother 2005; 49: 4895-902.
18. Mariné M, Serena C, Fernández-Torres B et al. Activities of flucytosine, fluconazole, amphotericin B, and micafungin in a murine model of disseminated infection by Candida glabrata. Antimicrob Agents Chemother 2005; 49: 4757-9.
19. Mariné M, Serena C, Pastor FJ et al. Combined antifungal therapy in a murine infection by Candida glabrata. J Antimicrob Chemother 2006; 58: 1295-8.
20. Barchiesi F, Spreghini E, Fothergill A et al. Caspofungin in combination with amphotericin B against Candida glabrata. Antimicrob Agents Chemother 2005; 49: 2546-9.
21. Gumbo T, Drusano GL, Liu W et al. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob Agents Chemother 2006; 50: 3695-700.
22. Gumbo T, Drusano GL, Liu Wet al. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob Agents Chemother 2007; 51: 968-74.
23. Spreghini E, Maida CM, Milici ME et al. Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. Antimicrob Agents Chemother 2008; 52: 513-7.
24. Spreghini E, Maida CM, Tomassetti S et al. Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. Antimicrob Agents Chemother 2008; 52: 1929-33.
25. Mariné M, Espada R, Torrado J et al. Efficacy of a new formulation of amphotericin B in a murine model of disseminated infection by Candida glabrata. J Antimicrob Chemother 2008; 61: 880-3.
26. Graybill JR, Bocanegra R, Luther M et al. Treatment of murine Candida krusei or Candida glabrata infection with L-743,872. Antimicrob Agents Chemother 1997; 41: 1937-9.
27. Abruzzo GK, Flattery AM, Gill CJ et al. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1997; 41: 2333-8.
28. Wiederhold NP, Najvar LK, Bocanegra R et al. In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob Agents Chemother 2007; 51: 1616-20.
29. Brzankalski GE, Najvar LK, Wiederhold NP et al. Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility. J Antimicrob Chemother 2008; 62: 1094-100.
30. Pfaller MA, Diekema DJ, Mendez M et al. Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program. J Clin Microbiol 2006; 44: 3551-6.
31. Barchiesi F, Spreghini E, Tomassetti S et al. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob Agents Chemother 2006; 50: 2719-27.
32. Louie A, Deziel M, Liu W et al. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 2005; 49: 5058-68.
33. Pfaller MA, Diekema DJ, Gibas DL et al. Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program, 2001 to 2005. J Clin Microbiol 2008; 46: 515-21.
34. Majithiya J, Sharp A, Palmar A et al. Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. J Antimicrob Chemother 2009; 63: 161-6.
35. Ostrosky-Zeichner L, Paetznick RI, Rodríguez J et al. Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and serum (1,3)-b-D-glucan levels. Antimicrob Agents Chemother 2009; 53: 1639-41.
36. Mariné M, Pastor FJ, Serena C et al. Efficacy of triazoles in a murine disseminated infection by Candida krusei. Antimicrob Agents Chemother 2009; 53: 3585-8.
37. Olver WJ, Scott F, Shankland GS. Successful treatment of Candida krusei fungemia with amphotericin B and caspofungin. Med Mycol 2006; 44: 655-7.
38. Conen A, Weisser M, Jörg CO et al. Candida krusei-a serious complication in patients with haematological malignancies: successful treatment with caspofungin. Transpl Infect Dis 2008; 10: 66-70.
39. Natale F, Castronovo A, Regoli D et al. Successful treatment with caspofungin of refractory Candida krusei candidemia in a very low birth weight preterm infant. Pediatr Infect Dis J 2009; 28: 452.
40. Pelletier R, Alarie I, Lagacé R et al. Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature. Med Mycol 2005; 43: 559-64.
41. Hakki M, Staab JF, Marr KA. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother 2006; 50: 2522-4.
42. Hautala T, Kakko S, Siitonen T et al. Clinical Candida krusei isolates remain susceptible during extensive exposure to antifungal drugs. Med Mycol 2009; 48: 79-84.
43. Kahn JN, Garcia-Effron G, Hsu MJ et al. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother 2007; 51: 1876-8.
44. Sili U, Yilmaz M, Ferhanoglu B et al. Candida krusei arthritis in a patient with hematologic malignancy: successful treatment with voriconazole. Clin Infect Dis 2007; 45: 897-8.
45. Spellberg B, Filler SC, Edwards JE Jr. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006; 42: 244-51.
46. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
47. Chamilos G, Lionakis MS, Lewis RE et al. Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species. J Infect Dis 2006; 193: 1014-22.
48. Trofa D, Gácser A, Nosanchuk JD. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev 2008; 21: 606-25.
49. van Asbeck EC, Clemons KV, Stevens DA. Candida parapsilosis: a review of its epidemiology, pathogenesis, clinical aspects, typing and antimicrobial susceptibility. Crit Rev Microbiol 2009; 35: 283-309.
50. Gonçalves SS, Amorim CS, Nucci M et al. Prevalence rates and antifungal susceptibility profiles of the Candida parapsilosis species complex: results from a nationwide surveillance of candidaemia in Brazil. Clin Microbiol Infect 2009; 16: 885-7.
51. Barchiesi F, Spreghini E, Tomassetti S et al. Caspofungin in combination with amphotericin B against Candida parapsilosis. Antimicrob Agents Chemother 2007; 51: 941-5.
52. Pfaller MA, Diekema DJ, Colombo AL et al. Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol 2006; 44: 3578-82.
53. Hernández S, González GM, McCarthy DI et al. Alternatives to amphotericin B for Candida rugosa infection. J Antimicrob Chemother 2004; 54: 477-80.
54. Colombo AL, Melo AS, Crespo Rosas RF et al. Outbreak of Candida rugosa candidemia: an emerging pathogen that may be refractory to amphotericin B therapy. Diagn Microbiol Infect Dis 2003; 46: 253-7.
55. Warn PA, Sharp A, Morrisey G et al. In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis. J Antimicrob Chemother 2002; 50: 1071-4.
56. Warn PA, Sharp A, Morrisey G et al. Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by Candida tropicalis. J Antimicrob Chemother 2005; 56: 590-3.
57. Barchiesi F, Maracci M, Baldassarri I et al. Tolerance to amphotericin B in clinical isolates of Candida tropicalis. Diagn Microbiol Infect Dis 2004; 50: 179-85.
58. Mariné M, Pastor FJ, Guarro J. Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. Antimicrob Agents Chemother 2010; 54: 530-2.
59. Martino R, Salavert M, Parody R et al. Blastoschizomyces capitatus infection in patients with leukemia: report of 26 cases. Clin Infect Dis 2004; 38: 335-41.
60. Serena C, Mariné M, Marimón R et al. Effect of antifungal treatment in a murine model of blastoschizomycosis. Int J Antimicrob Agents 2007; 29: 79-83.
61. Serena C, Rodriguez MM, Mariné M et al. Combined therapies in a murine model of blastoschizomycosis. Antimicrob Agents Chemother 2007; 51: 2608-10.
62. Serena C, Rodriguez MM, Mariné M et al. Micafungin combined with fluconazole, an effective therapy for murine blastoschizomycosis. J Antimicrob Chemother 2008; 61: 877-9.
63. Chittick P, Palavecino EL, Delashmitt B et al. Case of fatal Blastoschizomyces capitatus infection occurring in a patient receiving empiric micafungin therapy. Antimicrob Agents Chemother 2009; 53: 5306-7.
64. D'Antonio D, Mazzoni A, Iacone A et al. Emergence of fluconazole-resistant strains of Blastoschizomyces capitatus causing nosocomial infections in cancer patients. J Clin Microbiol 1996; 34: 753-5.
65. Serena C, Pastor FJ, Silgado F et al. Efficacy of micafungin in combination with other drugs in a murine model of disseminated trichosporonosis. Antimicrob Agents Chemother 2005; 49: 497-502.
66. Serena C, Gilgado F, Mariné M et al. Efficacy of voriconazole in a guinea pig model of invasive trichosporonosis. Antimicrob Agents Chemother 2006; 50: 2240-3.
67. Thibeault R, Champagne M, de Repentigny L et al. Fatal disseminated Trichosporon asahii infection in a child with acute lymphoblastic leukemia. Can J Infect Dis Med Microbiol 2008; 19: 203-5.
68. Kudo K, Terui K, Sasaki S et al. Voriconazole for both successful treatment of disseminated Trichosporon asahii infection and subsequent cord blood transplantation in an infant with acute myelogenous leukemia. Bone Marrow Transplant 2011; 46: 310-1.
69. Kim YJ, Kim SI, Kim YR et al. Successful treatment of septic shock with purpura fulminans caused by Trichosporon asahii in an immunocompetent patient. Ann Clin Lab Sci 2007; 37: 366-9.
70. Bassetti M, Bisio F, Di Biagio A et al. Trichosporon asahii infection treated with caspofungin combined with liposomal amphotericin B. J Antimicrob Chemother 2004; 54: 575-7.
71. Biasoli MS, Carlson D, Chiganer GJ et al. Systemic infection caused by Trichosporon asahii in a patient with liver transplant. Med Mycol 2008; 46: 719-23.
72. Pasqualotto AC. Differences in pathogenicity and clinical syndromes due to Aspergillus fumigatus and Aspergillus flavus. Med Mycol 2009; 47 Suppl 1: 261-70.
73. Hedayati MT, Pasqualotto AC, Warn PA et al. Aspergillus flavus: human pathogen, allergen and mycotoxin producer. Microbiology 2007; 153: 1677-92.
74. Orzechowski XM, Pasqualotto AC, Uchoa Sales MP et al. Invasive pulmonary aspergillosis due to mixed infection caused by Aspergillus flavus and Aspergillus fumigatus. Rev Iberoam Micol 2008; 25: 176-8.
75. Odds FC, Van Gerven F, Espinel-Ingroff A et al. Evaluation of possible correlation between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother 1998; 42: 282-8.
76. Bowman JC, Abruzzo GK, Flattery AM et al. Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus and Aspergillus nidulans. Antimicrob Agents Chemother 2006; 50: 4202-5.
77. Najvar LK, Cacciapuoti A, Hernández S et al. Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories. Antimicrob Agents Chemother 2004; 48: 758-64.
78. Mosquera J, Warn PA, Morrissey J et al. Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo. Antimicrob Agents Chemother 2001; 45: 1456-62.
79. Warn PA, Sharp A, Mosquera J et al. Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus. J Antimicrob Chemother 2006; 58: 1198-207.
80. Cacciapuoti A, Loebenberg D, Corcoram E et al. In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob Agents Chemother 2000; 44: 2017-22.
81. Cacciapuoti A, Halpern J, Mendrick C et al. Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection. Antimicrob Agents Chemother 2006; 50: 2587-90.
82. Chakrabarti A, Jatana M, Sharma SC. Rabbit as an animal model of paranasal sinus mycoses. J Med Vet Mycol 1997; 35: 295-7.
83. Nenoff P, Kliem C, Mittag M et al. Secondary cutaneous aspergillosis due to Aspergillus flavus in an acute myeloid leukaemia patient following stem cell transplantation. Eur J Dermatol 2002; 12: 93-8.
84. Chi CY, Fung CP, Liu CY. Aspergillus flavus epidural abscess and osteomyelitis in a diabetic patient. J Microbiol Immunol Infect 2003; 36: 145-8.
85. La Nasa G, Litera R, Maccioni A et al. Voriconazole for the treatment of disseminated nodular cutaneous aspergillosis in a patient affected by acute myeloid leukemia. Hematol J 2004; 5: 178-90.
86. Fraser JF, Mullany D, Natani S et al. Aspergillus flavus endocarditis - to prevaricate is to posture. Crit Care Resusc 2006; 8: 46-9.
87. Ali R, Ozkalemkas F, Ozcelik T et al. Invasive pulmonary aspergillosis: role of early diagnosis and surgical treatment in patients with acute leukemia. Ann Clin Microbiol Antimicrob 2006; 5: 17.
88. Rao K, Saha V. Medical management of Aspergillus flavus endocarditis. Pediatr Hematol Oncol 2000; 17: 425-7.
89. Pasticci MB, Barchiesi F, Fallani S et al. Clinical efficacy and tolerability of caspofungin in a renal transplant patient with Aspergillus flavus lung infection: case report. J Chemother 2006; 18: 549-53.
90. Li DM, Xiu DR, Li RY et al. Aspergillus flavus myositis in a patient after liver transplantation. Clin Transplant 2008; 22: 508-11.
91. Vandercasteele SJ, Boelaert JR, Verrelst P et al. Diagnosis and treatment of Aspergillus flavus sternal wound infections after cardiac surgery. Clin Infect Dis 2002; 35: 887-90.
92. Cobo M, Ramos A, Toquero J et al. Aspergillus infection of implantable-cardioverter-defibrillators and pacemakers: case report and literature review. Eur J Clin Microbiol Infect Dis 2007; 26: 357-61.
93. Sood S, Sharma R, Gupta S et al. Neuroaspergillosis in an immunocompetent patient. Ind J Med Microbiol 2007; 25: 67-9.
94. Dellepiane RM, Tortorano AM, Liotto N et al. Invasive Aspergillus nidulans infection in a patient with chronic granulomatous disease. Mycoses 2008; 51: 458-60.
95. Notheis G, Tarani L, Costantino F et al. Posaconazole for treatment of refractory invasive fungal disease. Mycoses 2006; 49 Suppl 1: 37-41.
96. Walsh TJ, Petraitis V, Petraitiene R et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis 2003; 188: 305-19.
97. Olenchock SA, Green FHY, Mentnech MS et al. In vivo pulmonary response to Aspergillus terreus spores. Comp Immunol Microbiol Infect Dis 1983; 6: 67-80.
98. Graybill JR, Hernández S, Bocanegra R et al. Antifungal therapy of murine Aspergillus terreus infection. Antimicrob Agents Chemother 2004; 48: 3715-9.
99. Barchiesi F, Spreghini E, Santinelli A et al. Efficacy of caspofungin against Aspergillus terreus. Antimicrob Agents Chemother 2005; 49: 5133-5.
100. Dannaoui E, Borel E, Persat F et al. Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis. J Med Microbiol 2000; 49: 601-6.
101. Warn PA, Morrisey G, Morrisey J et al. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. J Antimicrob Chemother 2003; 51: 913-9.
102. Johnson EM, Oakley KL, Radford SA et al. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J Antimicrob Chemother 2000; 45: 85-93.
103. Cooke FJ, Terpos E, Boyle J et al. Disseminated Aspergillus terreus infection arising from cutaneous inoculation treated with caspofungin. Clin Microbiol Infect 2003; 9: 1238-41.
104. Hachem RY, Kontoyiannis DP, Boktour MR et al. Aspergillus terreus. An emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer 2004; 101: 1594-600.
105. Lass-Flö rl C, Griff K, Mayr A et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Brit J Haematol 2005; 131: 201-7.
106. Steinbach WJ, Perfect JR, Schell WA et al. In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection. Antimicrob Agents Chemother 2004; 48: 3217-25.
107. Silva ME, Malogolowkin MH, Tall TR et al. Mycotic aneurysm of the thoracic aorta due to Aspergillus terreus: case report and review. Clin Infect Dis 2000; 31: 1144-8.
108. Trachana M, Roilides E, Gompakis N et al. Case report. Hepatic abscesses due to Aspergillus terreus in an immunodeficient child. Mycoses 2001; 44: 415-8.
109. Khoury H, Poch CF, Williams M et al. Acute myelogenous leukaemia complicated by acute necrotizing ulcerative gingivitis due to Aspergillus terreus. Leuk Lymphoma 2003; 44: 709-13.
110. Dignani MC, Anaissie E. Human fusariosis. Clin Microbiol Infect 2004; Suppl 1: 67-75.
111. Azor M, Cano J, Gené J et al. High genetic diversity and poor in vitro response to antifungals of clinical strains of Fusarium oxysporum. J Antimicrob Chemother 2009; 63: 1152-5.
112. O'Donnell K, Sutton DA, Rinaldi MG et al. Genetic diversity of human pathogenic members of the Fusarium oxysporum complex inferred from multilocus DNA sequence data and amplified fragment length polymorphism analyses: evidence for the recent dispersion of a geographically widespread clonal lineage and nosocomial origin. J Clin Microbiol 2004; 42: 5109-20.
113. Tortorano AM, Prigitano A, Dho G et al. Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy. Antimicrob Agents Chemother 2008; 52: 2683-5.
114. Alastruey-Izquierdo A, Cuenca-Estrella M, Monzón A et al. Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J Antimicrob Chemother 2008; 61: 805-9.
115. Ruíz-Cendoya M, Mariné M, Rodríguez MM et al. Interactions between triazoles and amphotericin B in treatment of disseminated murine infection by Fusarium oxysporum. Antimicrob Agents Chemother 2009; 53: 1705-8.
116. Lewis R, Hogan H, Howell A et al. Progressive fusariosis: unpredictable posaconazole bioavailability, and feasibility of recombinant interferon-gamma plus granulocyte macrophage-colony stimulating factor for refractory disseminated infection. Leuk Lymphoma 2008; 49: 163-5.
117. Gorman SR, Magiorakos AP, Zimmerman SK et al. Fusarium oxysporum pneumonia in an immunocompetent host. South Med J 2006; 99: 613-6.
118. Azor M, Gené J, Cano J et al. Universal in vitro antifungal resistance to genetic clades of the Fusarium solani species complex. Antimicrob Agents Chemother 2007; 51: 1500-3.
119. O'Donnell K, Sutton DA, Fothergill A et al. Molecular phylogenetic diversity, multilocus haplotype nomenclature, and in vitro antifungal resistance within the Fusarium solani species complex. J Clin Microbiol 2008; 46: 2477-90.
120. Anaissie EJ, Hachen R, Legrand C et al. Lack of activity of amphotericin B in systemic murine fusarial infection. J Infect Dis 1992; 165: 1155-7.
121. Guarro J, Pujol I, Mayayo E. In vitro and in vivo experimental activities of antifungal agents against Fusarium solani. Antimicrob Agents Chemother 1999; 43: 1256-7.
122. Lozano-Chiu M, Arikan S, Paetznick VL et al. Treatment of murine fusariosis with SCH 56592. Antimicrob Agents Chemother 1999; 43: 589-91.
123. Graybill JR, Najvar L, Gonzalez GM et al. Improving the mouse model for studying the efficacy of voriconazole. J Antimicrob Chemother 2003; 51: 1373-6.
124. Spellberg B, Schwartz J, Fu Y et al. Comparison of antifungal treatments for murine fusariosis. J Antimicrob Chemother 2006; 58: 973-9.
125. Ruíz-Cendoya M, Mariné M, Guarro J. Combined therapy in treatment of murine infection by Fusarium solani. J Antimicrob Chemother 2008; 62: 543-6.
126. Wiederhold NP, Najvar LK, Bocanegra R et al. Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. Antimicrob Agents Chemother 2010; 54: 1055-9.
127. Lortholary O, Obenga G, Biswas P et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother 2010; 54: 4446-50.
128. Stanzani M, Tumietto F, Vianelli N et al. Update on the treatment of disseminated fusariosis: focus on voriconazole. Ther Clin Risk Manag 2007; 3: 1165-73.
129. Ortoneda M, Capilla J, Pastor FJ et al. Efficacy of liposomal amphotericin B in treatment of systemic murine fusariosis. Antimicrob Agents Chemother 2002; 46: 2273-5.
130. Ruíz-Cendoya M, Pastor FJ, Guarro J. Treatment of murine Fusarium verticillioides infections with liposomal amphotericin B and terbinafine. Int J Antimicrob Agents 2010; 37: 58-61.
131. Ruíz-Cendoya M, Pastor FJ, Guarro J. Combined therapy against murine-disseminated infection by Fusarium verticillioides. Mycopathologia 2011; 171: 171-5.
132. Azor M, Gené J, Cano J et al. In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum. Antimicrob Agents Chemother 2008; 52: 2228-31.
133. Dornbusch HJ, Buzina W, Summerbell RC et al. Fusarium verticillioides abscess of the nasal septum in an immunosuppressed child: case report and identification of the morphologically atypical fungal strain. J Clin Microbiol 2005; 43: 1998-2001.
134. Sagnelli C, Fumagalli L, Prigitano A et al. Successful voriconazole therapy of disseminated Fusarium verticillioides infection in an immunocompromised patient receiving chemotherapy. J Antimicrob Chemother 2006; 57: 796-8.
135. Tezcan G, Ozhak-Baysan B, Alastruey-Izquierdo A et al. Disseminated fusariosis caused by Fusarium verticillioides in an acute lymphoblastic leukemia patient after allogeneic hematopoietic stem cell transplantation. J Clin Microbiol 2009; 47: 278-81.
136. Rothe A, Seibold M, Hoppe T et al. Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B. Ann Hematol 2004; 83: 394-7.
137. Neuburger S, Massenkeil G, Seibold M et al. Successful salvage treatment of disseminated cutaneous fusariosis with liposomal amphotericin B and terbinafine after allogeneic stem cell transplantation. Transpl Infect Dis 2008; 10: 290-3.
138. Nedelman JR, Gibiansky E, Robbins BA et al. Pharmacokinetics and pharmacodynamics of multiple-dose terbinafine. J Clin Pharmacol 1996; 36: 452-61.
139. Gilgado F, Cano J, Gené J et al. Molecular phylogeny of the Pseudallescheria boydii species complex: proposal of two new species. J Clin Microbiol 2005; 43: 4930-42.
140. Gilgado F, Cano J, Gené J et al. Different virulence of the species of the Pseudallescheria boydii complex. Med Mycol 2009; 47: 371-4.
141. Gilgado F, Serena C, Cano J et al. Antifungal susceptibilities of the species of Pseudallescheria boydii complex. Antimicrob Agents Chemother 2006; 50: 4211-3.
142. Gilgado F, Cano J, Gené J et al. Molecular and phenotypic data supporting distinct species statuses for Scedosporium apiospermum and Pseudallescheria boydii and the proposed new species Scedosporium dehogii. J Clin Microbiol 2008; 46: 766-71.
143. Capilla J, Serena C, Pastor J et al. Efficacy of voriconazole in the treatment of systemic scedosporiosis in neutropenic mice. Antimicrob Agents Chemother 2003; 47: 3976-8.
144. Capilla J, Mayayo E, Serena C et al. A novel murine model of cerebral scedosporiosis: lack of efficacy of amphotericin B. J Antimicrob Chemother 2004; 54: 1092-5.
145. González GM, Tijerina R, Najvar LK et al. Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays. Antimicrob Agents Chemother 2003; 47: 1436-8.
146. Rodríguez MM, Pastor FJ, Salas V et al. Experimental murine scedosporiosis: histopathology and azole treatment. Antimicrob Agents Chemother 2010; 54: 3980-4.
147. Capilla J, Guarro J. Correlation between in vitro susceptibility of Scedosporium apiospermum to voriconazole and in vivo outcome of scedosporiosis in guinea pigs. Antimicrob Agents Chemother 2004; 48: 4009-11.
148. Heath CH, Slavin MA, Sorrell TC et al. Population-based surveillance for scedosporiosis in Australia: epidemiology, disease manifestations and emergence of Scedosporium aurantiacum infection. Clin Microbiol Infect 2009; 15: 689-93.
149. Kooijman CM, Kampinga GA, de Hoog GS et al. Successful treatment of Scedosporium aurantiacum osteomyelitis in an immunocompetent patient. Surg Infect (Larchmt) 2007; 8: 605-10.
150. Morio F, Horeau-Langlard D, Gay-Andrieu F et al. Disseminated Scedosporium/Pseudallescheria infection after double-lung transplantation in patients with cystic fibrosis: case report and review of the literature. J ClinMicrobiol 2010; 48: 1978-82.
151. Stur-Hofmann K, Stos S, Saxa-Enenkel M et al. Primary cutaneous infection with Scedosporium apiospermum successfully treated with voriconazole. Mycoses 2009; doi:10.1111/j.1439-0507.2009.01799.x.
152. Rodriguez-Tudela JL, Berenguer J, Guarro J et al. Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med Mycol 2009; 7: 359-70.
153. Ortoneda M, Capilla J, Pujol I et al. Liposomal amphotericin B and granulocyte colony-stimulating factor therapy in a murine model of invasive infection by Scedosporium prolificans. J Antimicrob Chemother 2002; 49: 525-9.
154. Ortoneda M, Capilla J, Pastor FJ et al. Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosis. Diagn Microbiol Infect Dis 2004; 50: 247-51.
155. Bocanegra R, Najvar LK, Hernández S et al. Caspofungin and liposomal amphotericin B therapy of experimental murine scedosporiosis. Antimicrob Agents Chemother 2005; 49: 5139-41.
156. Rodríguez MM, Calvo E, Serena C et al. Effects of double and triple combinations of antifungal drugs in a murine model of disseminated infection by Scedosporium prolificans. Antimicrobial Agents Chemother 2009; 53: 2153-5.
157. Capilla J, Yustes C, Mayayo E et al. Efficacy of albaconazole (UR-9825) in treatment of disseminated Scedosporium prolificans infection in rabbits. Antimicrob Agents Chemother 2003; 47: 1948-51.
158. Troke P, Aguirrebengoa K, Arteaga C et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother 2008; 52: 1743-50.
159. Garzoni C, Markham L, Bijlenga P et al. Cladophialophora bantiana: a rare cause of fungal brain abscess: clinical aspects and new therapeutic options. Med Mycol 2008; 46: 481-6.
160. Revankar SG, Sutton DA, Rinaldi MG. Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin Infect Dis 2004; 38: 206-16.
161. Dixon DM, Polak A. In vitro and in vivo drug studies with three agents of central nervous system phaeohyphomycosis. Chemotherapy 1987; 33: 129-40.
162. Block ER, Jennings AE, Bennett JE. Experimental therapy of cladosporiosis and sporotrichosis with 5-fluorocytosine. Antimicrob Agents Chemother 1973; 3: 95-8.
163. Al-Abdely HM, Najvar L, Bocanegra R et al. Antifungal therapy of experimental cerebral phaeohyphomycosis due to Cladophialophora bantiana. Antimicrob Agents Chemother 2005; 49: 1701-7.
164. Mariné M, Pastor FJ, Guarro J. Combined antifungal therapy in a murine model of disseminated infection by Cladophialophora bantiana. Med Mycol 2009; 47: 45-9.
165. Levin TP, Baty DE, Fekete T et al. Cladophialophora bantiana brain abscess in a solid-organ transplant recipient: case report and review of the literature. J Clin Microbiol 2004; 42: 4374-8.
166. Lyons MK, Blair JE, Leslie KO. Successful treatment with voriconazole of fungal cerebral abscess due to Cladophialophora bantiana. Clin Neurol Neurosurg 2005; 107: 532-4.
167. Bonifaz A, Hoog S, McGinnis MR et al. Eumycetoma caused by Cladophialophora bantiana successfully treated with itraconazole. Med Mycol 2009; 47: 111-4.
168. Li DM, de Hoog GS. Cerebral phaeohyphomycosis - a cure at what lengths? Lancet Infect Dis 2009; 9: 376-83.
169. Kantarcioglu AS, de Hoog GS. Infections of the central nervous system by melanised fungi: a review of cases presented between 1999 and 2004. Mycoses 2004; 47: 4-13.
170. Polak A. Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice. Chemotherapy 1987; 33: 381-95.
171. Calvo E, Pastor FJ, Guarro J. Antifungal therapies in murine disseminated phaeohyphomycoses by Exophiala. J Antimicrob Chemother 2010; 65: 1455-9.
172. Graybill JR, Najvar L, Johnson E et al. Posaconazole therapy of disseminated phaeohyphomycosis in a murine model. Antimicrob Agents Chemother 2004; 48: 2288-91.
173. Negroni R, Helou SH, Petri N et al. Case study: posaconazole treatment of disseminated phaeohyphomycosis due to Exophiala spinifera. Clin Infect Dis 2004; 38: 15-20.
174. Zeng JS, Sutton DA, Fothergill AW et al. Spectrum of clinically relevant Exophiala species in the United States. J Clin Microbiol 2007; 45: 3713-20.
175. Bossler AD, Richter SS, Chavez AJ et al. Exophiala oligosperma causing olecranon bursitis. J Clin Microbiol 2003; 41: 4779-82.
176. Rivard RG, McCall S, Griffith ME et al. Efficacy of caspofungin and posaconazole in a murine model of disseminated Exophiala infection. Med Mycol 2007; 45: 685-9.
177. Aoyama Y, Nomura M, Yamanaka S et al. Subcutaneous phaeohyphomycosis caused by Exophiala xenobiotica in a non-Hodgkin lymphoma patient. Med Mycol 2009; 47: 95-9.
178. De Hoog GS, Attili-Angelis D, Vicente VA et al. Molecular ecology and pathogenic potential of Fonsecaea species. Med Mycol 2004; 42: 405-16.
179. Calvo E, Pastor FJ, Rodríguez MM et al. Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole. Antimicrob Agents Chemother 2009; 54: 919-23.
180. Madrid H, Ruiz-Cendoya M, Cano J et al. Genotyping and in vitro antifungal susceptibility of Neoscytalidium dimidiatum isolates from different origins. Int J Antimicrob Agents 2009; 34: 351-4.
181. Ruíz-Cendoya M, Madrid H, Pastor FJ et al. Evaluation of antifungal therapy in a neutropenic murine model of Neoscytalidium dimidiatum infection. Int J Antimicrob Agents 2010; 35: 152-5.
182. Sigler L, Summerbell RC, Poole L et al. Invasive Nattrassia mangiferae infections: case report, literature review, and therapeutic and taxonomic appraisal. J Clin Microbiol 1997; 35: 433-40.
183. Pastor FJ, Guarro J. Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections. Clin Microbiol Infect 2006; 12: 948-60.
184. Aguilar C, Pujol I, Sala J et al. Antifungal susceptibilities of Paecilomyces species. Antimicrob Agents Chemother 1998; 42: 1601-4.
185. Rodríguez MM, Pastor FJ, Serena C et al. Posaconazole efficacy in a murine disseminated infection caused by Paecilomyces lilacinus. J Antimicrob Chemother 2009; 63: 361-4.
186. Rodríguez MM, Pastor FJ, Serena C et al. Efficacy of voriconazole in a murine model of invasive paecilomycosis. Int J Antimicrob Agents 2010; 35: 362-5.
187. Nomeir AA, Kumari P, Hilbert MJ et al. Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys. Antimicrob Agents Chemother 2000; 44: 727-31.
188. Garzoni C, Garbino J. New azoles as first line therapy for Paecilomyces lilacinus transplant patients. Transpl Infect Dis 2008; 10: 149-50.
189. Mullane K, Toor AA, Kalnicky C et al. Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections. Transpl Infect Dis 2007; 9: 89-96.
190. Al-Abdely HM, Najvar L, Bocanegra R et al. SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ("Ramichloridium mackenziei"). Antimicrob Agents Chemother 2000; 44: 1159-62.
191. Al-Abdely HM, Alkhunaizi AM, Al-Tawfiq JA et al. Successful therapy of cerebral pheohyphomycosis due to Ramichloridium mackenziei with the new triazole posaconazole. Med Mycol 2005; 43: 91-5.
192. Pitisuttithum P, Negroni R, Graybill JR et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005; 56: 745-55.
193. Spellberg B, Walsh TJ, Kontoyiannis DP et al. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009; 48: 1743-51.
194. Greenberg RN, Mullane K, van Burik JA et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006; 50: 126-33.
195. Van Burik JA, Hare RS, Solomon HF et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42: 61-5.
196. Alvarez E, Stchigel AM, Cano J et al. Molecular phylogenetic diversity of the emerging mucoralean fungus Apophysomyces: proposal of three new species. Rev Iberoam Micol 2010; 27: 80-9.
197. Guarro J, Chander J, Alvarez E et al. Apophysomyces variabilis infections in humans. Emerg Infect Dis 2011; 17: 134-5.
198. Dannaoui E, Mouton JW, Meis JF et al. Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis. Antimicrob Agents Chemother 2002; 46: 1953-9.
199. Honda A, Kamei K, Unno H et al. A murine model of zygomycosis by Cunninghamella bertholletiae. Mycopathologia 1999; 144: 141-6.
200. Chakrabarti A, Ghosh A, Prasad GS et al. Apophysomyces elegans: an emerging zygomycete in India. J Clin Microbiol 2003; 41: 783-8.
201. Pastor FJ, Ruíz-Cendoya M, Pujol I et al. In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella. Antimicrob Agents Chemother 2010; 54: 4550-5.
202. Bibashi E, Sidi V, Kotsiou M et al. Pulmonary zygomycosis caused by Cunninghamella bertholletiae in a child with acute lymphoblastic leukemia. Hippokratia 2008; 12: 43-5.
203. Righi E, Giacomazzi CG, Lindstrom V et al. A case of Cunninghamella bertholletiae rhino-cerebral infection in a leukaemic patient and review of recent published studies. Mycopathologia 2008; 165: 407-10.
204. Garbino J, Myers C, Ambrosioni J et al. Report of a successful treatment of pulmonary Cunninghamella bertholletiae infection with liposomal amphotericin and posaconazole in a child with GvHD and review of the literature. J Pediatr Hematol Oncol 2010; 32: 85-7.
205. Dannaoui E, Meis JF, Loebenberg D et al. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother 2003; 47: 3647-50.
206. Mosquera J, Warn PA, Rodriguez-Tudela JL. Treatment of Absidia corymbifera infection in mice with amphotericin B and itraconazole. J Antimicrob Chemother 2001; 48: 583-6.
207. Barchiesi F, Spreghini E, Santinelli A et al. Posaconazole prophylaxis in experimental systemic zygomycosis. Antimicrob Agents Chemother 2007; 51: 73-7.
208. Sun QN, Najvar LK, Bocanegra R et al. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother 2002; 46: 2310-2.
209. Khan ZU, Ahmad S, Brazda A et al. Mucor circinelloides as a cause of invasive maxillofacial zygomycosis: an emerging dimorphic pathogen with reduced susceptibility to posaconazole. J Clin Microbiol 2009; 47: 1244-8.
210. Weitzman I, Della-Latta P, Housey G et al. Mucor ramosissimus Samutsevitsch isolated from a thigh lesion. J Clin Microbiol 1993; 31: 2523-5.
211. Rodríguez MM, Pastor FJ, Calvo E et al. Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. Antimicrob Agents Chemother 2009; 53: 5022-5.
212. Ting JY, Chan SY, Lung DC et al. Intra-abdominal Rhizopus microsporus infection successfully treated by combined aggressive surgical, antifungal, and iron chelating therapy. J Pediatr Hematol Oncol 2010; 32: 238-40.
213. Ibrahim AS, Avanessian V, Spellberg B et al. Liposomal amphotericin B, and not amphotericin B deoxycholate improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob Agents Chemother 2003; 47: 3343-4.
214. Ibrahim AS, Bowman JC, Avanessian V et al. Caspofungin inhibits Rhizopus oryzae 1,3-b-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 2005; 49: 721-7.
215. Ibrahim AS, Gebremariam T, Fu Y et al. Combination echinocandin- polyene treatment of murine mucormycosis. Antimicrob Agents Chemother 2008; 52: 1556-8.
216. Ibrahim AS, Gebremariam T, Husseiny MI et al. Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob Agents Chemother 2008; 52: 1573-6.
217. Ibrahim AS, Gebremariam T, Schwartz JA et al. Posaconazole monoor combination therapy for treatment of murine zygomycosis. Antimicrob Agents Chemother 2009; 53: 772-5.
218. Rodríguez MM, Calvo E, Mariné M et al. Efficacy of liposomal amphotericin B combined with gamma interferon or granulocytemacrophage colony-stimulating factor for treatment of systemic zygomycosis in mice. Antimicrob Agents Chemother 2009; 53: 3569-71.
219. Rodríguez MM, Pastor FJ, Sutton DA et al. Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice. Antimicrob Agents Chemother 2010; 54: 1665-9.
220. Rodríguez MM, Serena C, Mariné M et al. Posaconazole combined with amphotericin B, an effective therapy for a murine-disseminated infection caused by Rhizopus oryzae. Antimicrob Agents Chemother 2008; 52: 3786-8.
221. Spellberg B, Fu Y, Edwards JE Jr et al. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother 2005; 49: 830-2.
222. Van Cutsem J, Van Gerven F, Fransen J et al. Treatment of experimental zygomycosis in guinea pigs with azoles and amphotericin B. Chemotherapy 1989; 35: 267-72.
223. Spreghini E, Orlando F, Giannini D et al. In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility. J Antimicrob Chemother 2010; 65: 2158-63.
224. Abzug MJ, Walsh TJ. Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. Pediatr Infect Dis J 2004; 23: 769-73.
225. García-Díaz JB, Palau L, Pankey GA. Resolution of rhinocerebral zygomycosis associated with adjuvant administration of granulocytemacrophage colony-stimulating factor. Clin Infect Dis 2001; 32: 166-70.